Literature DB >> 30875545

Glucose-6-phosphate dehydrogenase activity in bipolar disorder and schizophrenia: Relationship to mitochondrial impairment.

Joseph S Puthumana1, William T Regenold2.   

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) is the first and rate-limiting enzyme of the pentose phosphate pathway that is essential to maintaining cellular redox balance. G6PD is especially plentiful in brain, and its deficiency has been linked to mood and psychotic disorders. We measured G6PD activity spectrophotometrically in four groups of 15 parietal somatosensory association cortex [Brodmann area (BA) 7] tissue samples (N = 60) from individuals with bipolar disorder (BPD); nonpsychotic unipolar major depression (UPD); schizophrenia (SCZ), and controls without psychiatric illness (CON). We report for the first time brain G6PD activity levels in these disorders. G6PD activity did not differ by brain group. In BPD and SCZ brains, however, it correlated significantly and inversely with percent of hexokinase 1 (HK1) in the tissue homogenate mitochondrial fraction as determined previously in another set of tissue samples obtained from the same brains and brain region. The correlation in SCZ brains lost statistical significance after controlling for brain pH. This finding indicates a positive relationship in BPD brains between G6PD activity and HK1 mitochondrial detachment, an indicator of mitochondrial impairment associated with increased mitochondrial generation of reactive oxygen species. We speculate that this relationship could be evidence that G6PD activity is proportionate to and may be a compensatory response to oxidative stress in the BA7 region of BPD brains. Future research should focus on clarifying the relationships among G6PD activity, markers of oxidative stress, brain pH, and evidence of mitochondrial impairment, particularly HK1 mitochondrial detachment, in brains of individuals with G6PD deficiency, BPD and SCZ.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Glucose-6-phosphate dehydrogenase; Hexokinase; Mitochondrial disorder; Oxidative stress; Schizophrenia

Mesh:

Substances:

Year:  2019        PMID: 30875545     DOI: 10.1016/j.jpsychires.2019.03.004

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  6 in total

Review 1.  Schizophrenia: a disorder of broken brain bioenergetics.

Authors:  Nicholas D Henkel; Xiajoun Wu; Sinead M O'Donovan; Emily A Devine; Jessica M Jiron; Laura M Rowland; Zoltan Sarnyai; Amy J Ramsey; Zhexing Wen; Margaret K Hahn; Robert E McCullumsmith
Journal:  Mol Psychiatry       Date:  2022-03-09       Impact factor: 13.437

Review 2.  Dosage Compensation in Females with X-Linked Metabolic Disorders.

Authors:  Patrycja Juchniewicz; Ewa Piotrowska; Anna Kloska; Magdalena Podlacha; Jagoda Mantej; Grzegorz Węgrzyn; Stefan Tukaj; Joanna Jakóbkiewicz-Banecka
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 3.  Contribution of Mitochondrial DNA Variation to Chronic Disease in East Asian Populations.

Authors:  Dayan Sun; Yang Wei; Hong-Xiang Zheng; Li Jin; Jiucun Wang
Journal:  Front Mol Biosci       Date:  2019-11-15

Review 4.  Insights into myelin dysfunction in schizophrenia and bipolar disorder.

Authors:  Marcela Valdés-Tovar; Alejandra Monserrat Rodríguez-Ramírez; Leslye Rodríguez-Cárdenas; Carlo E Sotelo-Ramírez; Beatriz Camarena; Marco Antonio Sanabrais-Jiménez; Héctor Solís-Chagoyán; Jesús Argueta; Germán Octavio López-Riquelme
Journal:  World J Psychiatry       Date:  2022-02-19

Review 5.  Insulin signaling as a therapeutic mechanism of lithium in bipolar disorder.

Authors:  Iain H Campbell; Harry Campbell; Daniel J Smith
Journal:  Transl Psychiatry       Date:  2022-08-29       Impact factor: 7.989

6.  Data-independent acquisition-based quantitative proteomic analysis of m.3243A>G MELAS reveals novel potential pathogenesis and therapeutic targets.

Authors:  Xueli Chang; Zhaoxu Yin; Wei Zhang; Jiaying Shi; Chuanqiang Pu; Qiang Shi; Juan Wang; Jing Zhang; Li Yan; Wenqu Yang; Junhong Guo
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.